AH股齊跌!上海醫藥A股大跌超7% 鎖價定增引入雲南白藥
格隆匯5月12日丨上海醫藥(601607.SH)跳空下跌,盤中一度跌超7%報20.18元,H股跌近5%報16.86港元;上海醫藥最新市值518億元人民幣。公司昨晚公吿,擬通過非公開發行A股股票引入雲南白藥作為戰略投資者。上海醫藥披露的定增預案顯示,擬向上海上實的全資子公司上海潭東企業諮詢服務有限公司、雲南白藥分別發行不超過8.53億股,發行價格為16.87元/股,其中上海潭東擬認購1.87億股,雲南白藥擬認購6.66億股,募資總額不超過143.84億元,募資淨額將全部用於補充營運資金及償還公司債務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.